Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryAlaska Medicaid Briumvi Prior Auth Coverage | Open…
    Ask Trek AI about this page
    CurrentAlaska MedicaidPolicy N/A

    Briumvi (ublituximab-xiiy) prior authorization

    Customize your policy alerts

    Sign up for all Alaska Medicaid policy alerts

    Know when Alaska Medicaid releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for Briumvi (ublituximab-xiiy) for treatment of relapsing forms of multiple sclerosis for Alaska Medicaid enrollees and specifies approval, denial, duration, dosing, and precautions that affect prescribers and patients.

    Policy Summary
    PayerAlaska Medicaid
    PolicyBriumvi (ublituximab-xiiy) prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and document patient age, relapsing MS diagnosis, neurologist involvement, prior therapy failures (≥2 in past 12 months), and pregnancy status; initial approval up to 6 months, reauthorization up to 12 months with documented improvement or stabilization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    J3590billing code
    12Reauth (months)
    6Initial (months)
    2Prior MS drugs required

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    18+
    Min age

    Coverage Criteria for Briumvi (ublituximab-xiiy)

    Initial Approval

    Covered when ALL of the following are met

    Initial approval requirements: 1. Patient is 18 years of age or older; 2. Diagnosis of a relapsing form of multiple sclerosis (clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease); 3. Prescribed by or in consultation with a neurologist or prescriber who specializes in MS; 4. Patient has had an ineffective response due to continued clinical relapse, intolerance, or contraindication to two or more MS drugs within the last 12 months; 5. For women of reproductive potential, provider attests the patient is not pregnant and will not become pregnant while treated with Briumvi.

    All conditions required

    Reauthorization

    Covered when ALL of the following are met

    Reauthorization requirements: Prescriber documents the patient has disease improvement or stabilization.

    Reauthorization up to 12 months when criteria met

    Concurrent administration of Briumvi with other disease‑modifying therapies for multiple sclerosis is an exclusion and will result in denial of prior authorization. Providers must not request Briumvi if the patient is receiving another disease‑modifying MS therapy at the same time; concurrent prescriptions are a specific denial trigger.

    Briumvi is contraindicated for patients with an active hepatitis B infection for the purposes of coverage under this policy. Use in patients with active hepatitis B will be denied and should not be requested for authorization.

    Coding and Dosing Information

    HCPCSHCPCS
    J3590Unclassified biologics (HCPCS) — listed in document for Briumvi
    Maintenance dosing interval
    Maintenance dose450 mg every 24 weeks
    Initial dosing regimen (for context)Initial dose 150 mg, then 450 mg two weeks later
    Billing codeHCPCS J3590 (listed with dosing)

    Provider Requirements, Authorization, and Denials

    Prior Authorization

    Prior authorization required; duration limits

    Prior authorization is required for Briumvi (HCPCS J3590). Initial approvals are allowed for up to 6 months; reauthorization may be granted for up to 12 months when the prescriber documents disease improvement or stabilization.

    • HCPCS code: J3590
    • Initial Approval: up to 6 months
    • Reauthorization: up to 12 months with documented improvement or stabilization
    Step Therapy

    Prior therapies required (step therapy)

    Before initiating Briumvi, the patient must have had an ineffective response, intolerance, or contraindication to two or more disease‑modifying therapies for multiple sclerosis within the prior 12 months.

    • Ineffective response defined as continued clinical relapse
    • Intolerance or documented contraindication to prior MS therapy

    Indications and Precautions

    Indication — Relapsing forms of multiple sclerosis
    Indication (FDA)Treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing‑remitting disease, and active secondary progressive disease in adults.
    Policy scopePrior authorization policy applies to Briumvi (ublituximab‑xiiy) for Alaska Medicaid enrollees with relapsing forms of MS.
    Age requirementPatient must be 18 years of age or older for approval per coverage criteria.
    Precautions and monitoring
    Serum immunoglobulin testingObtain quantitative serum immunoglobulins prior to initiating Briumvi; evaluate patients with low immunoglobulins with an immunologist.
    Delay for active infection or live vaccinesDelay Briumvi administration in patients with an active infection until resolved; avoid administration while receiving live‑attenuated vaccines.

    Background

    Briumvi (ublituximab‑xiiy) is a CD20‑directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing‑remitting disease, and active secondary progressive disease. Clinical use is intended for adults who have had inadequate response, intolerance, or contraindication to prior MS therapies and is administered per the dosing schedule described in the policy.

    Policy Summary
    PayerAlaska Medicaid
    PolicyBriumvi (ublituximab-xiiy) prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and document patient age, relapsing MS diagnosis, neurologist involvement, prior therapy failures (≥2 in past 12 months), and pregnancy status; initial approval up to 6 months, reauthorization up to 12 months with documented improvement or stabilization.
    SourceLink
    On This Page
    Coverage Criteria for Briumvi (ublituximab-xiiy)Coding and Dosing InformationProvider Requirements, Authorization, and DenialsIndications and PrecautionsBackground
  1. Required number of prior MS drugs: two or more within the last 12 months
  2. Documentation Required

    Required documentation to support authorization

    Document the patient meets all approval elements: age 18 or older; diagnosis of a relapsing form of MS; prescriber is a neurologist or in consultation with an MS specialist; prior inadequate response/intolerance/contraindication to ≥2 MS drugs in the last 12 months; and for women of reproductive potential, attestation patient is not pregnant and will not become pregnant while treated. Include relevant pre‑treatment and safety information such as quantitative serum immunoglobulin test results, infection status, premedication plan, and for reauthorization, objective documentation of disease improvement or stabilization.

    • Patient age (≥18 years)
    • Diagnosis: relapsing form of multiple sclerosis
    • Prescriber specialty: neurologist or MS specialist (or documented consultation)
    • Prior therapy history: ineffective response/intolerance/contraindication to ≥2 MS drugs within prior 12 months
    • For women of reproductive potential: pregnancy attestation
    • Pre‑treatment tests: quantitative serum immunoglobulins; infection status
    • Premedication plan (eg, corticosteroid and antihistamine)
    • Reauthorization: documentation of disease improvement or stabilization
    Denial Risk

    Denial triggers and contraindications

    Deny authorization when approval criteria are not met; concurrent use with other disease‑modifying therapies for MS or active hepatitis B infection are specific denial triggers.

    • Failure to meet all approval criteria
    • Concurrent prescription of Briumvi with other disease‑modifying MS therapies
    • Active hepatitis B infection
    Premedication recommendedPre‑medicate prior to each infusion with methylprednisolone (or equivalent corticosteroid) and an antihistamine (e.g., diphenhydramine).
    Reproductive safetyBriumvi may cause fetal harm; for women of reproductive potential, attest patient is not pregnant and will not become pregnant while treated.